United States: Orphan Drug Development And The Urgent Need For A New Approach

Last Updated: December 12 2018
Article by Lincoln Tsang

There are around 7,000 rare or 'orphan' diseases for which there currently exists no authorised or satisfactory method of treatment. Many are life-threatening or debilitating, and they particularly affect the very young, who often do not survive beyond adolescence. Without treatment, these patients' quality of life will be seriously affected and their lives may be shortened. This represents the grim reality that they and their families are facing.

There have been great advances in developing 'orphan drugs'. However, the potential for these new therapeutic approaches can only be realised if they are approved for clinical application. And treatments for rare diseases are much harder to get through the clinical trial and regulatory approval process.The clinical development of orphan drugs is fraught with many practical challenges, but two are really critical at the moment.

The first challenge is designing and running adequate clinical trials for orphan drugs. The randomised controlled trial, designed to minimise selection bias, has been accepted by regulatory authorities around the world as the gold standard. This design is commonly used in studies of new therapies designed to treat common diseases, and it will typically involve a large number of readily available clinical trial subjects.

However, this may not be a feasible model for the trials of orphan drugs, which treat a small population. Clinical trials in rare diseases necessarily enrol fewer trial subjects, and these people are unlikely to be concentrated in a particular geographical region. Add in the significant clinical differences between trial subjects, observed in many rare diseases, and this diminishes the power of the study.

Given the rarity of orphan diseases, arguably the greatest challenge in developing treatments is the timely and adequate recruitment of eligible trial participants. Many regulatory authorities use criteria intended for a larger patient population, such as demanding that two or more pivotal confirmatory studies be carried out. However, the authorities in both the EU and the US have recognised that such a requirement is more challenging to satisfy for treatments intended for orphan conditions, particularly for small and medium sized pharma companies with limited resources.

Because of the low incidence of the disease in each country, given its rarity, there is often a need to enrol patients from a number of countries to obtain a large enough sample size of trial subjects to establish the clinical efficacy. Since trial subjects are geographically dispersed, multi-centre studies must be initiated in various international centres of excellence. However, it can be very challenging to set up multiple trials to meet different regulations and requirements.

The solution would be a common trial design, but the varying regulatory approaches in different jurisdictions don't currently make this possible. Some regulatory authorities have established parallel scientific advice. However, the respective agencies do not have to arrive at the same view on the study design and it can therefore be difficult in practice to analyse the data derived from studies with disparate trial designs.

Greater cooperation between the regulatory authorities is therefore needed, to agree on the design of multi-centre clinical trials. This would greatly facilitate the development of orphan drugs. With strong international cooperation, it would often be possible to rely upon only one well-designed clinical study to elucidate the true treatment effects of a transformative method of treatment for all global regulatory authorities.

Once an orphan drug has been successfully trialled the second major challenge occurs: How, in this highly regulated sector, to get this innovative treatment onto the market in time to help patients with orphan conditions who will otherwise die? The regulatory authorities understandably require the dataset submitted for product approval to be sufficiently robust. On the other hand, patients with rare, life-threatening and debilitating conditions - and those involved in their care - expect, not unreasonably, expedited product approval to ensure timely access to such life-saving methods of treatment.

Contrary to popular belief, being designated as an orphan product does not automatically permit a regulatory authority to approve it more quickly or with less evidence than drugs intended for non-orphan populations. The standard of approval for orphan products is generally the same as the standard of approval for all other drugs.

Regulatory authorities do generally have some latitude to determine the level of evidence that is required to inform the benefit/risk assessment that underpins product approval. In the EU, the adopted regulatory standard for approval is that clinical data should be based on randomised clinical trials versus a placebo or, as appropriate, with an established medicinal product of proven therapeutic value. Any other design must be justified.

EU legislation does recognise that, in certain exceptional circumstances, a marketing authorisation may be granted on the basis of less comprehensive data, to address an unmet medical need. In addition, for certain rare, life-threatening and debilitating conditions, there is a regulatory pathway for a conditional marketing authorisation to be granted, giving immediate access to the product, if the manufacturer can prove an unmet medical need.

However, the regulatory authorities could benefit from clearer directions to fully embrace less conventional or common approaches to making a risk/benefit analysis for orphan drugs balance in exceptional circumstances. This would mean that new methods of treatment were not unjustifiably delayed or denied, subject to certain specific post-authorisation safeguards. Such an explicitly flexible and pragmatic approach would improve patient care in a clinical setting where there is a demonstrable unmet medical need.

It has been said when a method of treatment fails, researchers must be clear that there is a true lack of biological effect, rather than failure due to inadequate study design. Therefore, the approval process for orphan drugs ought to take full account of the detailed knowledge of the pathophysiology of the orphan disease and the pharmacology of the new method of treatment to facilitate the design of efficient clinical development processes. This would help to determine the amount of clinical data required to inform an assessment of clinical efficacy and safety.

International cooperation on clinical trials for orphan drugs, while highly desirable, will have a limited impact if patients in some countries can't access new therapies that come through the trials having demonstrated a favourable benefit/risk profile. Given increasingly cost conscious healthcare delivery systems, it's also important to ensure that patient access is not restricted because the new therapies are not accepted in some country on grounds of affordability.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

In association with
Related Topics
Related Articles
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Registration (you must scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions

Mondaq.com (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of www.mondaq.com

To Use Mondaq.com you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.


The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.


Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions